李媛;楚兰;张艺凡;

• 1:贵阳医学院神经病学教研室
• 2:贵阳医学院附属医院神经内科

摘要(Abstract)：

重症肌无力(MG)是一种神经肌肉接头(NMJ)传递障碍的获得性自身免疫性疾病,发病机制主要以体液免疫为主、细胞免疫依赖及补体参与。研究表明,MG的发病与多种淋巴细胞及其亚群、抗体、补体及各种细胞因子之间复杂的相互作用有关。故了解MG的免疫学发病机制对MG的诊断及治疗有重大意义。

关键词(KeyWords)： 重症肌无力;淋巴细胞;抗体;细胞因子

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李媛;楚兰;张艺凡;

Email:

参考文献(References)：

• [1]中国免疫学会神经免疫学分会,中华医学会神经病学分会神经免疫学组.重症肌无力诊断和治疗中国专家共识[J].中国神经免疫学和神经病学杂志,2012,19(6):401-408.
• [2]Dalakas M C.Novel future therapeutic options in myasthenia gravis[J].Autoimmun Rev,2013,12(9):936-941.
• [3]常婷.重症肌无力免疫学发病机制研究进展[J].中国神经免疫学和神经病学杂志,2011,18(5):357-360.
• [4]田亮,黄显雄,楚兰.淋巴细胞亚群在重症肌无力患者中的变化及其研究进展[J].医学信息(上旬刊),2011,24(9):6300-6302.
• [5]张永强,张临友,许博.细胞因子在重症肌无力发病机制中的研究进展[J].国际免疫学杂志,2012,35(5):367-370.
• [6]易芳芳,朱雯华,赵重波.重症肌无力与细胞因子[J].中国临床神经科学,2014(4):470-474.
• [7]Liu R,Zhou Q,La Cava A,et al.Expansion of regulatory T cells via IL-2/anti-IL-2mAb complexes suppresses experimental myasthenia[J].Eur J Immunol,2010,40(6):1577-1589.
• [8]史杰婧,刘洪波,刘丽,等.白细胞介素在重症肌无力发病机制中的作用[J].中国医药指南,2013(14):82-83.
• [9]Poussin MA,Goluszko E,Franco JU,et al.Role of IL-5during primary and secondary immune response to acetylcholine receptor[J].J Neuroimmunol,2002,125(1-2):51-58.
• [10]林婧,卜碧涛.细胞因子与重症肌无力的免疫学发病机制[J].神经损伤与功能重建,2011,6(1):65-68.
• [11]李柱一,常婷.免疫相关基因单核苷酸多态性与重症肌无力易患性及临床特点的相关性[J].中华神经科杂志,2013,46(7):433-437.
• [12]Kong QF,Sun B,Bai SS,et al.Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta[J].J Neuroimmunol,2009,207(1-2):83-91.
• [13]邓茂林,杨欢,肖波,等.重症肌无力患者外周血FOXP3、TGF-B1的变化及其与血清AChR抗体的关系[J].中风与神经疾病杂志,2009,26(3):320-323.
• [14]陈玉萍,魏东宁,肖漓.重症肌无力患者外周血T淋巴细胞亚群分布特点及临床意义[J].医学研究生学报,2011,24(9):944-947.
• [15]杜伟伟,李劲频,陈泽志,等.自身免疫调节因子对EAMG模型小鼠发病的影响[J].中国神经免疫学和神经病学杂志,2014,21(3):157-160.
• [16]Hardy RR.B-1Bcell development[J].J Immunol,2006,177(5):2749-2754.
• [17]Hohlfeld R,Wekerle H.Reflections on the“intrathymic pathogenesis”of myasthenia gravis[J].J Neuroimmunol,2008,5(201-202):21-27.
• [18]牛延良,姜炎,孙乐羽,等.重症肌无力患者B细胞激活及其与激素治疗相关性研究[J].重庆医学,2014,43(30):4075-4077.
• [19]Carter R H,Myers R.Germinal center structure and function:lessons from CD19[J].Semin Immunol,2008,20(1):43-48.
• [20]易芳芳,赵重波,朱雯华,等.小剂量他克莫司添加治疗难治性全身型重症肌无力的疗效及对外周血CD19+BAFF-R+B细胞的影响[J].中国临床神经科学,2014,22(2):171-175.
• [21]Chevrier S,Genton C,Kallies A,et al.CD93is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche[J].Proc Natl Acad Sci USA,2009,106(10):3895-3900.
• [22]Conti-Fine BM,Milani M,Kaminski HJ.Myasthenia gravis:past,present,and future[J].J Clin Invest,2006,116(11):2843-2854.
• [23]Zhang B,Tzartos J S,Belimezi M,et al.Autoantibodies to lipoprotein-related protein 4 in patients with doubleseronegative myasthenia gravis[J].Arch Neurol,2012,69(4):445-451.
• [24]Feng HY,Wang HY,Liu WB,et al.The high frequency and clinical feature of seronegative myasthenia gravis in Southern China[J].Neurol Sci,2013,34(6):919-924.
• [25]吴君霞.重症肌无力相关自身抗体的研究进展[J].医学综述,2013,19(19):3491-3493.
• [26]曾秋明.血清阴性重症肌无力研究进展[J].中国神经免疫学和神经病学杂志,2012,19(6):465-467,470.
• [27]Hoch W,McConville J,Helms S,et al.Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies[J].Nat Med,2001,7(3):365-368.
• [28]Ohta K,Shigemoto K,Fujinami A,et al.Clinical and experimental features of MuSK antibody positive MG in Japan[J].Eur J Neurol,2007,14(9):1029-1034.
• [29]Zisimopoulou P,Evangelakou P,Tzartos J,et al.A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4in myasthenia gravis[J].J Autoimmun,2014,52:139-145.
• [30]Zhang W,Coldefy AS,Hubbard SR,et al.Agrin binds to the N-terminal region of Lrp4protein and stimulates association between Lrp4and the first immunoglobulin-like domain in muscle-specific kinase(MuSK)[J].J Biol Chem,2011,286(47):40624-40630.
• [31]Zhang B,Shen C,Bealmear B,et al.Autoantibodies to agrin in myasthenia gravis patients[J].PLoS One,2014,9(3):e91816.
• [32]Higuchi O,Hamuro J,Motomura M,et al.Autoantibodies to low-density lipoprotein receptor-related protein 4in myasthenia gravis[J].Ann Neurol,2011,69(2):418-422.
• [33]Pevzner A,Schoser B,Peters K,et al.Anti-LRP4autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis[J].J Neurol,2012,259(3):427-435.
• [34]Szczudlik P,Szyluk B,Lipowska M,et al.Antititin antibody in early-and late-onset myasthenia gravis[J].Acta Neurol Scand,2014,130(4):229-233.
• [35]Suzuki S,Utsugisawa K,Nagane Y,et al.Three types of striational antibodies in myasthenia gravis[J].Autoimmune Dis,2011,2011:740583.